Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Unity Biotechnology Inc (UBX) USD0.0001

Sell:$6.04 Buy:$6.05 Change: $0.12 (1.95%)
Market closed |  Prices as at close on 3 December 2020 | Switch to live prices |
Change: $0.12 (1.95%)
Market closed |  Prices as at close on 3 December 2020 | Switch to live prices |
Change: $0.12 (1.95%)
Market closed |  Prices as at close on 3 December 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.

Contact details

3280 Bayshore Blvd
United States
+1 (650) 4161192

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$313.78 million
Shares in issue:
52.91 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Keith Leonard
    Chairman of the Board
  • Nathaniel David
    President, Co-Founder, Director
  • Anirvan Ghosh
    Chief Executive Officer, Director
  • Lynne Sullivan
    Chief Financial Officer, Chief Accounting Officer
  • Dan Marquess
    Chief Scientific Officer
  • Tamara Tompkins
    General Counsel and Corporate Secretary
  • Jamie Dananberg
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.